HUE025822T2 - Elvitegravir-t, Cobicistat-t, Emtricitabine-t és Tenofovir-t tartalmazó kétrétegû tabletták - Google Patents

Elvitegravir-t, Cobicistat-t, Emtricitabine-t és Tenofovir-t tartalmazó kétrétegû tabletták Download PDF

Info

Publication number
HUE025822T2
HUE025822T2 HUE10703766A HUE10703766A HUE025822T2 HU E025822 T2 HUE025822 T2 HU E025822T2 HU E10703766 A HUE10703766 A HU E10703766A HU E10703766 A HUE10703766 A HU E10703766A HU E025822 T2 HUE025822 T2 HU E025822T2
Authority
HU
Hungary
Prior art keywords
formula
compound
tablet
layer
tablets
Prior art date
Application number
HUE10703766A
Other languages
English (en)
Inventor
Reza Oliyai
Mark M Menning
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025822(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE025822T2 publication Critical patent/HUE025822T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (12)

  1. Szabaáateö igesypößtöfc
    1, TéleSte, amely taït&îïôsz dső réteget és a második réteget, éhöl a) »2 e!sl íéieg tartalmaz: «gyűlését Képiéi i szerire:
    I es wgyületeí Képlet il szerisi: &
    és opcionálisan gyógyseerészetilsg elfogadható hordozóanyagot; és fe> a második réteg tartalmaz: vegyiiletet Képiét ilí szerint:
    M ; és Képiéi IV söjáí-í
    IV > és opcionálisait gyrigyázfiréseetiieg elfogadható Ifordbzóssyägöt,
  2. 2. Az: I... $géö$p#í azerimí tabletta, ahol az els® rétég érinilezésbéP vág a: igásűdlá réteggel:.
  3. 3. Az 1-2. igénypontok bármely »k>r szerinti mbletta, ahol a Képlet I SJ?«É3Í végyüfet; súlyaránya $ Képiét 11 sKeííati s'egy^fcifex visâôiïÿkva 1,0 * 0,5.
  4. 4, Az 1 -3. igéttyponiok bármelyike szerimi tabletta, abel az első réteg! továbbá tártiilmüií több sziliktt részecskét.
  5. 5, Az 1-3. ígénypnrifök: batÄlylke «tei tabletta, ahöl ;s Képiét II; szérmti; éegyület ssalika; részecskékkel van összekapcsolva.
    4. Az 1-5. igénypontok bármelyiké szerinti tabletta, amely tartalmazza a képlet 1' szerinti vegyüíet: !.5ömg-jst ά 10%; a képlet II szerinti yegylilet 150 mg-pt ét:Ö%;a képlet ÓI szerinti vegyülő? 20Θ aig-jáí: A .jpi ;,éá É k-éplpt ÍV szerimi vegyül«? lOD arg-lát a- 10%. 7. A 6. igénypont szerinti tabletta, amely tartalmazza a képlet I szerinti wgyület 130 níg-ját 3 $%. 5. A4, igéttypent szerístltabletta, amely tartalmazza a képiéi ! szerinti vegyüíet 150 mg-jat A 2% % Az 6-3. igénypontok bármelyike szerinti tabletta, amely tartalmazza a képlet II szerinti vegyüld 150 mg-jái a· 5%. H). Az 6-8, sgénypbbtpk bármelyike szerinti tabletta, amely tartalmazza a képlet II szénné vegyüíet 150 mariát ·.·.·. 2% .
  6. 11, Az 6-10, igénypontok bármelyike szerinti tabletta, amely tartalmazza s képlet: M szerinti vegyüíet 200 mg-ja; -.·.·. 3% , 12;, Ait 0-10,: igénypontok bâîaHeiyAeszeîiiïti: tabletta,: aíttely tartalmazza a kéjjlet 111 szerinti vegyül«? 200 mg-ját A 5% ,·.
  7. 13, Az 4-12:, igénypontok bármelyike szerinti, tabletta, amely tartalmazza a képlet IV szerinti vegyél«? 3Ö0 nag-já? * 3%,
  8. 14, Az 6-11, igénypimfok bátmelyike szerinti tabletta, amely tartalmazza a: képlet: IV szerinti yégyület 300 tag-jät A 234:...
  9. 15, Az 1-14. igénypoxstok Isámmlpke szerinti tabletta, amely továbbá tartalmaz a gyôgÿszesVszdileg eltügpdhíiié aöráözéanyagot. }<>. Az 1-13, Igénypontit bármelyiké szerinti tabletta, amely íormnlálva van egységadag alakban.
  10. 17, Az 1-10: Igénypomit bármelyiké szerinti tabletta, amply Osrmnlálva van napi egyszeri adagban.
  11. 18. Eprás az 1, Igénypont szerinti tabletta clóáílitására, amely tartalmazza: a képlet 1 szerinti vegyöíetet és képlet II szérián vegyüieiet tartalmazó kompozíció korstpresszálását első sajtolt réteggé; ÍKmzaa<ir|k a képlet 111 szerinti vegySleíei: és a IV képlet szerinti sót az első sajtolt: réteghez # kompresszáljnk, hogy a tablettát rendelkezésre bocsássuk. !9. Az í. jgáaypont szerinti tabletta, .ameïy «II aMveétezőkbofc
  12. 20, Tablets, atndv â Í8. igénypont szerint vas döállilm
HUE10703766A 2009-02-06 2010-02-04 Elvitegravir-t, Cobicistat-t, Emtricitabine-t és Tenofovir-t tartalmazó kétrétegû tabletták HUE025822T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06

Publications (1)

Publication Number Publication Date
HUE025822T2 true HUE025822T2 (hu) 2016-04-28

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10703766A HUE025822T2 (hu) 2009-02-06 2010-02-04 Elvitegravir-t, Cobicistat-t, Emtricitabine-t és Tenofovir-t tartalmazó kétrétegû tabletták

Country Status (31)

Country Link
US (2) US20100285122A1 (hu)
EP (1) EP2393485B1 (hu)
JP (2) JP5611242B2 (hu)
KR (2) KR101645759B1 (hu)
CN (1) CN102307573B (hu)
AP (1) AP3250A (hu)
AR (1) AR075369A1 (hu)
AU (1) AU2010210598B2 (hu)
BR (1) BRPI1008664A2 (hu)
CA (1) CA2750521A1 (hu)
CL (1) CL2011001885A1 (hu)
CY (1) CY1116852T1 (hu)
DK (1) DK2393485T3 (hu)
EA (2) EA030123B1 (hu)
EC (1) ECSP11011307A (hu)
ES (1) ES2548886T3 (hu)
HK (1) HK1164737A1 (hu)
HR (1) HRP20151009T1 (hu)
HU (1) HUE025822T2 (hu)
IL (1) IL214227A (hu)
MX (1) MX2011008289A (hu)
NZ (1) NZ594214A (hu)
PE (1) PE20110994A1 (hu)
PL (1) PL2393485T3 (hu)
PT (1) PT2393485E (hu)
SG (3) SG2014007744A (hu)
SI (1) SI2393485T1 (hu)
SM (1) SMT201500266B (hu)
TW (1) TWI444367B (hu)
UY (1) UY32424A (hu)
WO (1) WO2010091197A2 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2487163T (pt) * 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
EP2646005B1 (en) * 2010-11-29 2019-06-26 Formac Pharmaceuticals N.v. Compressed formulations of ordered mesoporous silicas
ES2651212T3 (es) * 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
UY34262A (es) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CN104105484A (zh) * 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法
WO2013130766A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
PT4070788T (pt) 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
PT3411378T (pt) 2016-02-02 2020-07-28 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
EP1564210B9 (en) 2002-11-20 2010-03-31 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2487163T (pt) * 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos

Also Published As

Publication number Publication date
SG2014007744A (en) 2014-05-29
JP2012517432A (ja) 2012-08-02
EA201190125A1 (ru) 2012-01-30
CA2750521A1 (en) 2010-08-12
NZ594214A (en) 2013-05-31
CN102307573B (zh) 2013-09-11
DK2393485T3 (en) 2015-10-26
KR101645759B1 (ko) 2016-08-04
CL2011001885A1 (es) 2012-05-25
TWI444367B (zh) 2014-07-11
PL2393485T3 (pl) 2015-12-31
IL214227A (en) 2017-01-31
WO2010091197A2 (en) 2010-08-12
US20100285122A1 (en) 2010-11-11
JP2014221845A (ja) 2014-11-27
KR101738325B1 (ko) 2017-05-19
EA030123B1 (ru) 2018-06-29
HRP20151009T1 (hr) 2015-10-23
EA021313B1 (ru) 2015-05-29
PT2393485E (pt) 2015-10-23
KR20160093100A (ko) 2016-08-05
AP3250A (en) 2015-05-31
AU2010210598B2 (en) 2015-03-05
SG10201706215UA (en) 2017-08-30
TW201040142A (en) 2010-11-16
UY32424A (es) 2010-09-30
SMT201500266B (it) 2016-01-08
KR20110122729A (ko) 2011-11-10
EP2393485A2 (en) 2011-12-14
JP5611242B2 (ja) 2014-10-22
EP2393485B1 (en) 2015-07-29
AR075369A1 (es) 2011-03-30
SG173544A1 (en) 2011-09-29
AP2011005857A0 (en) 2011-10-31
ECSP11011307A (es) 2011-10-31
AU2010210598A1 (en) 2011-08-25
US20150150810A1 (en) 2015-06-04
IL214227A0 (en) 2011-09-27
EA201491658A1 (ru) 2015-05-29
WO2010091197A3 (en) 2011-06-03
HK1164737A1 (en) 2012-09-28
CN102307573A (zh) 2012-01-04
ES2548886T3 (es) 2015-10-21
MX2011008289A (es) 2011-09-15
CY1116852T1 (el) 2017-04-05
SI2393485T1 (sl) 2015-10-30
JP5911927B2 (ja) 2016-04-27
PE20110994A1 (es) 2012-01-24
BRPI1008664A2 (pt) 2016-03-08

Similar Documents

Publication Publication Date Title
EP2393485B1 (en) Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
EP1753406B2 (en) Coated tablet formulation and method
CA2688721A1 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
CN104363896A (zh) 恩替卡韦的药物组合物及制造方法
CN103068374B (zh) 代谢型谷氨酸受体5(mglu5)拮抗剂的药物组合物
CN105407875A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
AU2015200637B2 (en) Tablets for combination therapy
WO2022023206A1 (en) Bilayer tablet comprising ezetimibe and atorvastatin
JP2001270827A (ja) ベンズイミダゾール系化合物含有錠剤
JP7362302B2 (ja) レベチラセタムを含有する錠剤とその製造方法
WO2016206663A1 (en) A pharmaceutical formulation of sofosbuvir